N/A N=63 Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos
Unwanted Tattoos
Primary: Tattoo Clearance — 2.5; 3.0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos
Unwanted Tattoos
Primary: Tattoo Clearance Percentage Using a Photographic Scale — 84.7 percentage of clearance
N/A N=15 Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos
Unwanted Tattoos
Primary: Number of Patients With Tattoo Clearance — 3; 5 Participants
N/A N=20 Evaluation of the 755nm Alexandrite for Unwanted Tattoos
Unwanted, Non Cosmetic, Tattoos
Primary: Tattoo Clearance — 2.875; 4.25 score on a scale — p=.0077
N/A N=20 Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos
Tattoos
Primary: Tattoo Clearance Using Photographic Evaluation — 15; 6; 2 Tattoos
N/A N=44 Reactions of Older Adults Driving After Cannabis Exposure
Chronic Pain
Primary: Simulated Driving Performance Task Measuring Divided Attention — 3.42; 2.57 units on a scale
N/A N=42 Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal
Tattoo Removal
Primary: Tattoo Clearing at 6 Weeks Post-final Laser Treatment for Each Treatment Arm as Assessed by Blinded Reviewers. — 2.54; 2.17 score on a scale
N/A N=47,396 Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support
Alzheimer Disease · Dementia
Primary: Hospital Transfers — 1.2; 1.3 number of hospital transfers — p=0.3313
Phase 3 N=50 A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Prevalence of Postoperative Gut Dysfunction — 13; 15 Participants — p=0.264
N/A N=264 Patient Priority Care for Older Adults With Multiple Chronic Conditions
Multiple Chronic Conditions
Primary: Treatment Burden — 11.9; 11.6; 12.7; 17.9 score on a scale
N/A N=10 Response Inhibition in Tourette Syndrome
Tourette Syndrome
Primary: Stop Signal Reaction Time (SSRT) — 249; 245 milliseconds — p=0.49
N/A N=11 Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
Hypertrichosis
Primary: Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment — 41; 27 percent reduction
N/A N=153 Addressing the Health Concerns of VA Women With Sexual Trauma
Stress Disorders, Post-Traumatic · Intimate Partner Violence · Alcohol-Related Disorders
Primary: Change in Number of Health Risks — 1.38; 1.05 number of risks
Phase 3 N=356 Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination — 26.3; 29.7; 32.5; 13.2 Percentage of participants
Phase 2 N=225 A Study to Test Different Doses of BI 1569912 in People With Depression
Depressive Disorder, Major
Primary: Change From Baseline in MADRS Total Score at Week 6 — -10.3; -13.6; -10.6; -10.0 Units on a scale — p=0.5414